ReviewFrontiers in immunology2018
Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 182 citations in OpenAlex.
- Connective tissue disease-associated interstitial lung disease: immune profiling and correlation of immune cells with pulmonary function in SSc-ILD.Annals of medicine · 2026Article
- Heart-reactive antibody levels differentially associate with ventricular function in hereditary cardiomyopathies.BMC cardiovascular disorders · 2026Article
- MAKAAO, an open access resource linking human autoantibodies and autoimmune diseases.Communications medicine · 2026Article
- High Immunological Activity and the Re-Evaluation of Anti-SSA/SSB Antibodies as Prognostic Markers for Major Organ Damage in Systemic Lupus Erythematosus.International journal of rheumatic diseases · 2026Article
- Expression of VISTA on peripheral blood mononuclear cells in Systemic lupus erythematosus: association with disease activity and treatment status.Clinical and experimental medicine · 2026Article
- Exploring the Lung-Liver Axis in Pulmonary Arterial Hypertension.Comprehensive Physiology · 2026Article
- Toward Precision Health in Autoimmunity and Immune-Related Adverse Events: The Autoantibody Reactome, Spatial Omics, and Multimodal Data Integration.Biomedicines · 2026Article
- Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations.JHEP reports : innovation in hepatology · 2026Article
- Association between systemic inflammatory response index and cardiovascular disease risk in rheumatoid arthritis patients: a machine learning based on US and Chinese cohorts.Clinical rheumatology · 2026Article
- An atypical immunophenotype in generalized eruptive histiocytosis: a case report of coexisting scattered S-100 positivity and seropositivity for Anti-nRNP/Sm antibodies.Frontiers in immunology · 2026Article
- Atypical Interplay of Dermatomyositis, Metastatic Caecal Carcinoma, and Connective Tissue Disease.Cureus · 2026Article
- Management and treatment of early rheumatoid arthritis, process and barriers among rheumatologists in Spain: a Delphi consensus.BMC rheumatology · 2025Article
- A practical approach to joint pain in primary care.Singapore medical journal · 2025Article
- Diagnostic Utility of Antibodies to Extractable Nuclear Antigens in the Absence of Positive Antinuclear Antibodies.Cureus · 2025Article
- Anti-protein arginine methyltransferase 5 (PRMT5) antibodies is associated with interstitial lung disease in rheumatoid arthritis.Scientific reports · 2025Article
- Atopic Dermatitis and Autoimmune Connective Tissue Diseases: Systematic Review and Meta-Analysis.Dermatology practical & conceptual · 2025Review
- A tRNA gene potential to activate interferon signaling involves selective termination and is suppressible by La protein/SSB.Nucleic acids research · 2025Article
- Diagnosis of Systemic Rheumatic Disease Using the Connective Tissue Disease Screen.Antibodies (Basel, Switzerland) · 2025Review
- Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects.Journal of rheumatic diseases · 2025Review
- Treating connective tissue disease-associated interstitial lung disease - think outside the box: a perspective.European respiratory review : an official journal of the European Respiratory Society · 2025Review
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Connective tissue diseases (CTDs) such as systemic lupus erythematosus, systemic sclerosis, myositis, Sjögren's syndrome, and rheumatoid arthritis are systemic diseases which are often associated with a challenge in diagnosis. Autoantibodies (AAbs) can be detected in these diseases and help clinicians in their diagnosis. Actually, pathophysiology of these diseases is associated with the presence of antinuclear antibodies. In the last decades, many new antibodies were discovered, but their implication in pathogenesis of CTDs remains unclear. Furthermore, the classification of these AAbs is nowadays misused, as their targets can be localized outside of the nuclear compartment. Interestingly, in most cases, each antibody is associated with a specific phenotype in CTDs and therefore help in better defining either the disease subtypes or diseases activity and outcome. Because of recent progresses in their detection and in the comprehension of their pathogenesis implication in CTD-associated antibodies, clinicians should pay attention to the presence of these different AAbs to improve patient's management. In this review, we propose to focus on the different phenotypes and features associated with each autoantibody used in clinical practice in those CTDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.